Full-Time

Senior Specialty Representative

Respiratory Biologics

Posted on 4/15/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$120.3k - $147.1k/yr

+ Bonus + Stock-based long-term incentives

Senior

Birmingham, AL, USA

Territory covers: Tuscaloosa, Montgomery, Auburn, Columbus, GA. Relocation is not provided for this role.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • Bachelor's Degree and 3 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
  • OR
  • Associate degree and 6 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
  • OR
  • High school diploma/GED and 8 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
Responsibilities
  • Provide current and comprehensive clinical knowledge of Amgen's products and effectively communicate the clinical and economic benefits of the products to medical professionals
  • Perform as a sales leader to achieve territory sales by implementing and delivering branded sales messages strategies
  • Utilize internal and external relationships to service and manage accounts which includes: ensuring product access, resolving/triage reimbursement issues, and maintaining product contracts
  • Analyze business effectiveness of sales activities and territory analysis, as well as develop territory plans with the District Manager
  • Have passion for our products and sustain that passion through the entire sales cycle while always building our brand, never losing sight of how we serve patients
  • Partner with other colleagues to share best practices and be in a state of continuous curiosity and learning to help grow as a Senior Specialty Representative
  • Leverage passion for disease state awareness, industry, regulatory and competitive changes to deliver agreed results
Desired Qualifications
  • Three or more years of sales experience within pharmaceutical, biotech or medical device industry Product or hospital sales experience in the areas of oncology, nephrology, dermatology, rheumatology, inflammation, cardiology, neurology, endocrinology, hepatology, gastroenterology or infectious diseases; and the diseases and treatments involved with these specialties
  • Local market knowledge
  • A Bachelor's degree in Life Sciences or Business Administration
  • Adaptability with our Core Competencies: Planning and Organizing; Leveraging Business, Industry, and Technical Knowledge; Communicating with Impact; Driving for Results; and Cultivating Internal and External Relationships.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a significant portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.

INACTIVE